Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

NCT02302742 · View on ClinicalTrials.gov ↗

Study Summary

PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).

Study Locations (11)

Kansas

  • Hays Medical Center Dreiling-Schmidt Cancer Institute — Hays
  • KCCC West — Kansas City
  • KCCC Overland Park — Overland Park
  • Overland Park Regional Medical Center — Overland Park
  • Salina Regional Health Center - Tammy Walker Cancer Center — Salina
  • The University of Kansas Cancer Center — Westwood

Missouri

  • Universtiy Health — Kansas City
  • KCCC South — Kansas City
  • Research Medical Center — Kansas City
  • KCCC - North — Kansas City
  • KCCC Lee's Summit — Lee's Summit

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2011-03-22
Est. Completion 2026-12

Sponsor

University of Kansas Medical Center

454 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02302742

The ClinicalTrials.gov registry entry for NCT02302742 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 454 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02302742 reports 11 study locations spanning 2 distinct geographic areas — top geographies include Kansas, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02302742 about?

NCT02302742 is a clinical study titled "Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry". PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).

What is the current status of trial NCT02302742?

This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2011-03-22. Estimated completion is 2026-12.

What conditions does trial NCT02302742 study?

This clinical trial studies the following conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT02302742?

This trial is sponsored by University of Kansas Medical Center, which has 454 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02302742 being conducted?

This trial has 11 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial